[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100127320":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":11,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Sumitomo Pharma Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: DSP-3025",{"label":15,"type":16,"description":11,"interventionNames":17},"2","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":11},"DRUG","DSP-3025",[9],{"type":21,"name":25,"description":11,"armGroupLabels":26,"otherNames":11},"Placebo",[15],[28],{"facility":29,"status":11,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":11},"Kitasato University East Hospital","Sagamihara","Kanagawa","228-8520","Japan","JP",{"type":36,"coordinates":37},"Point",[38,39],139.24167,35.56707,{"lat":39,"lon":38},{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100127320","phase-1-dsp-3025-study-of-healthy-male-volunteers-and-seasonal-allergic-rhinitis-male-patients-out-of-season-100127320",false,"NCT00925678","DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season","A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 and 25 kg\u002F m2 and a weight between 50 and 80 kg\n* No clinically relevant abnormal findings\n* History of cedar and\u002For Japanese cypress pollen induced seasonal allergic rhinitis for at least the previous 2 years (only Allergic rhinitis)\n\nExclusion Criteria:\n\n* Acute illness which requires medical intervention\n* Definite or suspected personal history of adverse drug reactions or drug hypersensitivity\n* Clinical relevant disease or disorder (past or present)\n* A history of asthma",true,"MALE","20 Years","39 Years",{"count":55,"type":56},72,"ESTIMATED","INTERVENTIONAL",[59],"PHASE1","Investigate safety\u002Ftolerability after a single dose intranasal administration of DSP-3025 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season.",[62,63],"Allergic Rhinitis","Healthy Volunteer","COMPLETED","2022-04-09",{"date":67,"type":68},"2022-04-12","ACTUAL",{"date":70,"type":11},"2009-06",{"name":5,"class":6},1]